Aurora Cannabis Inc. has tapped a veteran biopharmaceutical executive to drive the company's global commercial expansion, naming Faris El Refaie as Executive Vice‑President, Global Commercial, the company announced this week. The appointment, effective Sept. 28, 2026, creates a new senior role focused on accelerating growth in Aurora's medical cannabis business across multiple regulated markets.
Role created to consolidate global commercial efforts
In the newly created position, Faris El Refaie will oversee Aurora's global commercial function with responsibility for refining the company's medical cannabis market strategy, aligning its international portfolio and scaling customer engagement and commercial capabilities. The company said the remit covers operations in Canada, Europe, Australia and New Zealand, as well as "other international markets" as Aurora expands its footprint.
- Start date: Sept. 28, 2026
- Title: Executive Vice‑President, Global Commercial
- Focus areas: market strategy, portfolio alignment, customer engagement, commercial capability building
In a statement, Aurora's executive leadership framed the hire as a strategic move at a pivotal time for the company.
"We're beyond excited to welcome Faris to Aurora at such a pivotal time in the company's global growth journey," said Miguel Martin, Executive Chairman and CEO of Aurora. "Faris brings decades of executive leadership in the biopharmaceutical industry ... that will no doubt be additive to our global strategy and the company's overall ability to lead."
Executive experience mirrors regulated‑market environment
The company highlighted El Refaie's roughly 25 years of experience across highly regulated pharmaceutical organisations, including roles at JAMP Pharma Group, GSK and AstraZeneca. Aurora said his background spans innovative medicines, oncology, specialty care, vaccines and consumer healthcare and includes commercial responsibilities across Canada, the United States, Europe and Asia.
Aurora framed the appointment as part of an effort to build on its medical cannabis platform, which it says is "grounded in science, quality and patient care." The company added that El Refaie has led commercial transformations, global product strategies and cross‑functional teams — experience Aurora said will help it "unlock new opportunities across its international medical cannabis business."
What the announcement means locally
For residents who follow the cannabis industry and local corporate developments, the hire signals Aurora's continued focus on scaling its medical business beyond domestic markets. While the company did not provide details on staffing, facilities or direct local investments tied to the appointment, the creation of a senior global commercial role underscores a strategic emphasis on international market growth.
Observers of the sector will likely watch how Aurora translates the executive's pharmaceutical experience into commercial gains in regulated medical cannabis markets, and how the company's global portfolio alignment evolves as regulators and patient access frameworks change.
| Element | Detail |
|---|---|
| Appointee | Faris El Refaie |
| Title | Executive Vice‑President, Global Commercial |
| Effective | Sept. 28, 2026 |
| Primary markets named | Canada, Europe, Australia, New Zealand, other international markets |
The company emphasised that the appointment aligns with Aurora's broader aim to deliver medical cannabis to more patients worldwide by strengthening presence in key markets. Management's public remarks tied the hire directly to advancing commercial growth and leadership.
As Aurora positions itself for international expansion, stakeholders in Aurora and beyond will be watching subsequent announcements for specifics on product rollouts, partnerships and any operational changes that accompany the company's stated commercial ambitions.
